No published articles yet for this condition. Check back soon.
0 published articles · Updated continuously
24 trials tracked for Neurotoxicity: 15 in phase 3 or 4 and 9 with published results. The most-cited published study has 1218 citations.
Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Among the established trials, the most recently registered evidence concerns anti-pseudomonal cephalosporin exposure and neurotoxicity: in a Phase 4 trial of 2,634 patients, Major Adverse Kidney Events Within 14 Days (MAKE14) occurred in 124 versus 114 patients, and delirium- and coma-free days to day 14 were 14 in both groups 1.
For cognitive outcomes after brain radiotherapy, stereotactic radiosurgery was associated with cognitive deterioration-free survival post-radiation of 3.0 versus 3.7 with whole-brain radiotherapy (p<0.0001), while local control of the surgical bed was 87.1 versus 80.4 (p=0.00068); change in quality-of-life at 6 months did not differ significantly (p=0.31) 4. In a separate Phase 3 trial, memantine did not significantly change HVLT-R delayed recall at 24 weeks (0 versus -0.9, p=0.059) or across 8, 16, and 52 weeks (p=0.0692), but median time to neurocognitive failure was 2.6 versus 2.3 (p=0.01) 6. Ginkgo biloba showed no significant difference in cognitive dysfunction on the HSCS overall score (p=0.84) 12.
For chemotherapy-induced peripheral neurotoxicity, several agents failed to show benefit: baclofen/amitriptyline/ketamine gel did not differ from control on total sensory (p=0.90), motor (p=0.50), or autonomic (p=0.50) neuropathy scores 7; acetyl-L-carnitine did not improve 12-week FACT-Taxane neurotoxicity (p=0.17), TOI functional status (p=0.92), or FACIT-fatigue (p=0.20) 9; lamotrigine did not change average daily pain (p=0.56), ECOG neuropathy score (p=0.36), or quality of life (p=0.25) 10; ketamine/amitriptyline NP-H cream did not change average daily peripheral neuropathy intensity (p=0.363) 11; and vitamin E did not reduce grade 2+ sensory peripheral neuropathy (34% versus 29%, p=0.43), dose reductions (p=0.49), or early chemotherapy discontinuation (p=1.00) 13.
Calcium gluconate evidence is mixed: one Phase 3 trial found no significant difference in grade 2+/3+ chronic cumulative neurotoxicity percentages, time to onset, or cumulative oxaliplatin dose (p=0.89) 8, whereas another found a lower percentage of grade 2+ chronic neuropathic adverse events (22% versus 41%, p=0.038) with a time-to-onset difference of borderline significance (p=0.0503) and no difference in average duration (p=0.6556) 15. Duloxetine was associated with greater reduction in average pain from week 1 to week 5 (1.06 versus 0.34, p=0.003), greater improvement in pain-related functional interference (7.9 versus 3.5), and improvement in FACT/COG-NTX total score (2.44 versus 0.87, p=0.03) 5. Glutamic acid neurotoxicity scores on a scored neurologic examination were 26 versus 34 14.
AI synthesis of 17 cited trials, updated Oct 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.